Clinical Trials' Racial Divide: Merck's Quest for Inclusion
The underrepresentation of Black Americans in clinical trials is a pressing concern that researchers and advocates are working to address. According to Dr. Adrelia Allen, executive director of representation in clinical trials at Merck, only 8% of clinical trial participants are Black, despite making up nearly 14% of the U.S. population.
The lack of diversity in clinical trials can lead to a limited understanding of how investigational medicines work across populations, which is why it's essential to increase representation and inclusion in these studies. Dr. Allen notes that willingness to participate is not the main obstacle, but rather a lack of awareness and access to information.
Merck has launched a grassroots effort to improve clinical trial representation, starting with its own trials. Dr. Allen shares her personal experience as a pharmacist and medical doctor who recognized the need for diversity in studies after noticing that patients she was enrolling didn't resemble her own community.
Cancer research is particularly affected by this issue, with Black men being 1.5 times more likely to develop prostate cancer and 2.2 times more likely to die from it compared to white men. Despite making up only 3% of participants in prostate cancer clinical trials, Black patients are often hesitant to join due to past atrocities and concerns about being treated as 'guinea pigs'.